Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh (ETVAX/dmLT)
A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh
Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
This PHASE1/PHASE2 trial investigates Escherichia Coli Diarrhea and is currently completed. International Centre for Diarrhoeal Disease Research, Bangladesh leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jul 2017 — Dec 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Centre for Diarrhoeal Disease Research, Bangladesh
- PATH
- Scandinavian Biopharma AB
For direct contact, visit the study record on ClinicalTrials.gov .